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ABSTRACT
Background Disease progression in heart failure (HF)
reﬂects derangements in neurohormonal systems, and
biomarkers of these systems can help to establish the
diagnosis and assess the prognosis. Serial
measurements of the precursor peptides of the
natriuretic and vasopressin systems (midregional
proatrial natriuretic peptide (MR-proANP) and C-terminal
provasopressin (copeptin), respectively) should add
incremental value to risk stratiﬁcation in ambulatory
patients with HF.
Methods and results A cohort of 187 patients with
class IIIeIV HF was prospectively enrolled, with
biomarkers collected every 3 months over 2 years and
analysed in relation to death/transplantation. Time-
dependent analyses (dichotomous and continuous
variables) showed that increases in MR-proANP (HR 7.6,
95% CI 1.85 to 31.15, p<0.01) and copeptin (HR 2.7,
95% CI 1.27 to 5.61, p¼0.01) were associated with
increased risk, but, in multivariate analysis adjusted for
troponin T (cTnT) $0.01 ng/ml, only raised MR-proANP
remained an independent predictor (HR 5.49, 95% CI
1.31 to 23.01, p¼0.02). Combined increases in MR-
proANP and copeptin (HR 9.01, 95% CI 1.24 to 65.26,
p¼0.03) with cTnT (HR 11.1, 95% CI 1.52 to 80.85,
p¼0.02), and increases $30% above already raised
values identiﬁed the patients at greatest risk (MR-
proANP: HR 10.1, 95% CI 2.34 to 43.38, p¼0.002;
copeptin: HR 11.5, 95% CI 2.74 to 48.08, p<0.001).
Conclusions A strategy of serial monitoring of MR-
proANP and, of lesser impact, copeptin, combined with
cTnT, may be advantageous in detecting and managing
the highest-risk outpatients with HF.
INTRODUCTION
Despite advances in therapy, chronic heart failure
(HF) is associated with an adverse prognosis
1 2 and
progresses in the absence of overt clinical events.
34
Multiple neurohormonal pathways are activated,
some of which are causally related and some are an
effect of HF itself.
5 One pathway, the natriuretic
peptide system, is associated with adverse
outcomes.
6e8 Not only are they prognostic when
initially measured but we have shown that the
combination of B-type natriuretic peptide (BNP)
and troponin T (cTnT) measured every 3 months
over 2 years provides incremental information
about the progression of HF in outpatients.
9 Most
previous studies that evaluated changes over time
monitored patients for short periods (typically
3e6 months) and/or used only single point-in-time
measurements.
81 0 e13 Given the importance of risk
stratiﬁcation, additional biomarkers that probe
different neurohormonal pathways may further
help to deﬁne disease progression and prognosis,
which is likely to be dynamic and change over time.
In addition, such biomarkers may provide novel
pathophysiological insights and thus be synergistic
with BNP/N-terminal (NT)-proBNP-guided
therapy
14 and standard clinical assessment (eg,
New York Heart Association (NYHA) class) in
making therapeutic decisions.
Midregional proatrial natriuretic peptide
(MR-proANP)
15 and C-terminal provasopressin
(copeptin), a 39-amino-acid peptide derived from
the prohormone preprovasopressin and cosecreted
with arginine vasopressin from the posterior pitu-
itary,
16 are precursor peptides related to different
pathophysiological mechanisms in HF progression
and have prognostic potential.
10 11 17 Recent data
suggest that MR-proANP provides comparable
diagnostic information to BNP in the acute
setting.
18 19
How much incremental information might be
obtained from these new biomarkers, especially
when assessed frequently over a prolonged period
of time, remains to be evaluated. Accordingly, we
measured MR-proANPand copeptin concentrations
in outpatients with HF using the methods of design
and analysis we reported previously for BNP and
cTnT.
9 Our hypotheses were that serial measure-
ments at long-term follow-up would provide inde-
pendent risk stratiﬁcation similar, but additive, to
that of BNP and cTnT
20 21 and thus enhance
identiﬁcation of outpatients with HF who are at
increased risk and would beneﬁt from more inten-
sive management. We pursued alternative analyses,
assessing these analytes as continuous variables as
well to make sure that we did not place them at
a disadvantage by using the same analysis strategy
as we previously used for BNP and cTnT.
9
METHODS
Patients and study design
A cohort of 200 patients with NYHA class III and
IV HF was prospectively enrolled from June 2001 to
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Biomarkers and heart diseaseJanuary 2004. Informed consent was obtained after a primary
medical evaluation. Patients were excluded if cardiac revascu-
larisation was anticipated within 6 months of enrolment, they
were awaiting cardiac transplantation, or they had experienced
an episode of acute HF decompensation within the past 30 days.
Patients were followed at prespeciﬁed 3-month intervals
(63 weeks) for 24 months. The study was approved by the
Mayo Foundation Institutional Review Board and included
only patients who provided written consent as required by
Minnesota Statute 144.335/ CFR 21 (Part 50).
Study protocol
Blood samples were collected in serum and EDTA, immediately
placed on ice, processed and stored at  708C in divided aliquots
until batch analysis was performed for each biomarker. Samples
were collected and stored with the pre-hoc speciﬁcation for
multiple analyte evaluations. Precursor peptides (MR-proANP
and copeptin) have been shown analytically to be very stable
over time when stored at  708C.
10 11 Clinicians and investiga-
tors were blinded to biomarker results. Left ventricular ejection
fraction was derived by echocardiography performed up to
3 months before enrolment. An updated patient history and
physical examination were completed at each follow-up visit by
the primary HF specialist involved, as well as basic laboratory
studies. Changes in drugs were recorded. Mean6SD follow-up
duration was 18.967.8 months.
Biomarker measurements
MR-proANP and copeptin concentrations were measured in
EDTA plasma by immunoluminometric assays (CT-proAVP LIA
(copeptin) and MR-proANP LIA) provided by BRAHMS
Aktiengeselschaft (Henningsdorf, Germany) on a Berthold
LB952 Auto CliniLumat Luminescence analyser. Copeptin
(interassay and intra-assay CVs <10%) and MR-proANP
(interassay CV 2.3%, intra-assay CV 3.6%) were measured with
coated-tube immunoluminometric assays. The details for BNP
and cTnT measurements have previously been reported.
9
Raised MR-proANP and BNP concentrations were deﬁned as
values >95th centile of a normal population adjusted for age and
gender.
10 22 Raised copeptin concentrations were deﬁned as
>7.1 pmol/l for women and >9.4 pmol/l for men.
11 Raised
cTnT was deﬁned as values $0.01 ng/ml.
23 24 Renal function
was determined by calculating estimated glomerular ﬁltration
rate (ml/min/1.73 m
2) using the modiﬁcation of diet in renal
disease equation.
25
Statistical analysis
Continuous variables are reported as mean with SD and median
with 25th and 75th centile IQRs. Categorical variables are
reported as frequency of total values. Logarithmic trans-
formation was performed to achieve approximate normal
distribution for the biomarkers. The goal was to evaluate the
relationships over time between the time until death or cardiac
transplantation and serial MR-proANP and copeptin concen-
trations in relation to cTnT and BNP using the identical meth-
odology and statistical analysis approach as used in our previous
report
9 to ensure consistency in data handling. All modelling
was performed with Cox proportional hazards models and
executed using two different models. First, we included each
biomarker as a continuous variable in univariate and multivar-
iate models. Then, to facilitate the large numbers of cTnT
observations that were below the limit of detection (ie,
<0.01 ng/ml), we entered two variables, one a dichotomous
variable indicating that the cTnT was below detectable levels
(normal) and one variable using the logarithmic continuous
measurements for cTnT values that were above 0.01 ng/ml.
Second, MR-proANP, copeptin and BNP (but not cTnT) data
were analysed on the basis of tertiles for risk prediction and to
facilitate clinical interpretation. Third, we categorised each of
the biomarkers dichotomously as either ‘raised’ or ‘not raised’
based on the 95th centile of normal population data and the
0.01 ng/ml cut-off point for cTnT. Results from the Cox
proportional hazards models are presented as HRs with corre-
sponding 95% CIs, p values and C-statistics.
26 Because of
repeated data collection for all biomarkers and variety of enrol-
ment times, enrolment (single value) and time-dependent (serial
values) analysis methods were used. KaplaneMeier survival
curves summarise follow-up outcomes and account for
changes in biomarker concentrations during the study period.
Differences in survival curves were evaluated with log-rank
tests. Likewise, in the time-dependent Cox multivariable
models, patients were included in the initial proper risk set, but
allowed to move between risk sets (higher risk and lower risk)
over time. All other variables in these models are based on values
at enrolment. Time-dependent Cox models were also used to
evaluate changes in biomarkers between 3-month follow-up
periods. To be included in this analysis, patients had to be
followed to at least one 3-month visit after enrolment. Because
changes in cTnT, but not BNP, were found to be statistically
signiﬁcant in these models, only cTnT was used to assess
possible interactive effects. Analyses were carried out using SAS
V.9 software
27 or S-plus V.7.
28
RESULTS
Table 1 shows the clinical and demographic characteristics of the
cohort. Of the 200 patients enrolled, 13 had insufﬁcient
biomarker data, and therefore results are reported for 187
participants. Mean6SD duration of HF was 41.9644.2 months
(median 31 months). Eight patients died before the initial 3-
month follow-up visit and provided only baseline data. Six (3%)
patients went on to cardiac transplantation, and 55 (29%)
patients died during the study.
At enrolment, MR-proANP and copeptin concentrations were
raised in 157 (84%) and 133 (71%) of patients, respectively.
Another 17 and 31 patients, respectively, developed new
increases during the study. BNP was raised at enrolment in 122
patients (65%), and cTnT concentrations were $0.01 ng/ml in
103 patients (55%). During the study, another 31 patients each
developed new increases in BNP and cTnT.
Baseline single-sample biomarker analysis
Univariate analysis was undertaken using all baseline variables
including standard risk predictors of age, diabetes, hypertension,
left ventricular ejection fraction and renal function. The
following were shown to be the most signiﬁcant predictors in
this cohort: increasing NYHA class IIIeIV (HR 3.46, 95% CI
1.75 to 6.83, p<0.001), presence of biventricular pacing (HR
2.79, 95% CI 1.27 to 6.14, p¼0.011), myocardial infarction
history (HR 1.90, 95% CI 1.13 to 3.19, p¼0.015), stroke history
(HR 2.29, 95% CI 1.04 to 5.04, p¼0.039), raised BNP (HR 2.54,
95% CI 1.35 to 4.78, p¼0.004) and raised cTnT (HR 2.69, 95%
CI 1.54 to 4.72, p<0.001). Reduced risk was associated with
a non-ischaemic aetiology of HF (HR 0.52, 95% CI 0.28 to 0.98,
p¼0.043) and higher glomerular ﬁltration rate (HR 0.98, 95% CI
0.96 to 0.99, p¼0.005). Covariate regression analyses for death/
transplantation based on single-sample measurements at study
enrolment for MR-proANP and copeptin in an interaction model
with cTnT showed that only when increases were combined
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Biomarkers and heart diseasewith cTnT did these biomarkers predict worse outcomes (MR-
proANP, HR 4.19, 95% CI 2.50 to 11.67, p¼0.006; copeptin, HR
3.69, 95% CI 1.56 to 8.73, p¼0.003). When baseline peptide
values were analysed as continuous variables (log transformed)
in regression analysis, all biomarkers were univariate predictors
of death/transplantation (table 2).
A model for covariate correction was developed before
assessment of MR-proANP, copeptin, cTnT or BNP effects and
included the signiﬁcant univariate variables that were shown to
be the most appropriate adjustment for this cohort given the
number of events (NYHA class, history of myocardial infarction,
and biventricular pacing) and without over-ﬁtting the model.
Multivariate analysis with adjustment for these univariate
predictors (all data are not shown given that they revealed
similar coefﬁcients) showed baseline MR-proANP, copeptin and
cTnT to be signiﬁcant predictors of worse outcome (table 2).
Time-dependent serial biomarker analysis
Univariate time-dependent analyses (over 2 years) for prediction
of death/transplantation showed that serial measurements of
MR-proANP (HR 7.60, 95% CI 1.85 to 31.15, p¼0.0048) and
copeptin (HR 2.67, 95% CI 1.27 to 5.61, p¼0.0096) were highly
predictive. Figure 1A, B illustrates KaplaneMeier survival anal-
ysis for these biomarkers including concentrations obtained at
the last follow-up visit or the follow-up visit preceding an event.
An increase in MR-proANP was the most potent predictor of
poor outcome, and concentrations remaining normal were
protective. In multivariate time-dependent modelling with serial
MR-proANP and copeptin values adjusted for cTnT $0.01 ng/
ml, raised MR-proANP (HR 5.49, 95% CI 1.31 to 23.01, p¼0.02),
but not copeptin (HR 1.89, 95% CI 0.89 to 4.13, p¼0.6332),
persisted as an independent predictor. Multivariate analysis that
included adjustment for the baseline univariate clinical predic-
tors as described above revealed that the HR for cTnTwas 2.31
(p¼0.003), and, with the separate additions of MR-proANP and
copeptin to the model, the HR for MR-proANP was signiﬁcant
(4.56, p¼0.039), while copeptin did not contribute to risk
prediction in the presence of raised cTnT (table 3).
When analysed in time-dependent models by tertiles, BNP,
MR-proANP and copeptin revealed that the risk of death/trans-
plantation was increased with increasing tertile, but risk predic-
tion was not uniform. For BNP, tertile 2 (BNP >115e337 pg/ml)
was not different from tertile 1 (#115 pg/ml), while tertile 3
(>337 pg/ml) was signiﬁcantly different from tertile 1 (HR 3.06,
Table 1 Baseline demographics and clinical characteristics of patient
cohort
Variable Mean±SD
Median
(25e75% IQR)
No of
patients (%)
Age (years) 71610 73 (64e79) 187
Male gender 143 (76.4)
Caucasian/Native American 185/2
NYHA
Class III 172 (92.0)
Class IV 15 (8.0)
Duration of heart
failure (months)
41.9644.2 31 (6e65) 187
LVEF (%) 27.3612.2 24 (18e33) 187
Weight (kg) 87623 82 (73e97) 187
Height (cm) 17269 174 (166e178) 187
BMI (kg/m
2) 29.266.7 28 (25e32.5) 187
Heart rate (beats/min) 71613 71 (62e80) 187
Systolic BP (mm Hg) 113621 110 (98e124) 187
Diastolic BP (mm Hg) 63611 60 (58e70) 187
Haemoglobin (g/dl) 12.561.7 12.4 (11.1e13.7) 99
Serum creatinine, mg/dL 1.660.6 1.5 (1.3e1.9) 187
GFR (ml/min/1.73 m
2)4 6 615 45 (35e57) 187
Potassium (mEq/l) 4.460.9 4.4 (4.1e4.7) 187
Sodium (mEq/l) 13964.1 140 (137e142) 184
MR-proANP (pmol/l) 3956304 333 (202e476) 187
Copeptin (pmol/l) 24.4624.7 16.6 (7.3e31.1) 187
BNP (pg/ml) 4086423 305 (118e521) 187
Troponin T (ng/ml) 0.07460.491 0.013 (0.005e0.035) 187
Aetiology of HF
Ischaemic 101 (54.0)
IDCM 56 (29.9)
Hypertension 5 (2.6)
Valvular 7 (3.7)
Other 18 (9.6)
Diabetes 28 (15)
Hypertension 120 (64)
Hyperlipidaemia 121 (65)
COPD 49 (26)
History of CABG 82 (44)
BiV pacemaker 27 (14)
AICD 50 (27)
History of MI 91 (49)
History of CVA 12 (6)
Never smoker 68 (36)
Atrial ﬁbrillation 86 (46)
Aortic stenosis 20 (11)
Aortic regurgitation 46 (24)
Mitral regurgitation 141 (75)
Tricuspid regurgitation 130 (70)
History of valve replacement surgery 17 (9)
Drugs
ACE1 140 (75)
ARB 34 (18)
b-blocker 147 (78)
Aldosterone blocker 50 (27)
Digoxin 113 (60)
Diuretic 173 (92)
Aspirin 114 (61)
Nitrates 55 (29)
Antidysrhythmics 40 (21)
ACE1, angiotensin converting enzyme inhibitor; AICD, automatic implantable cardioverter
deﬁbrillator; ARB, angiotension receptor blocker; BiV, biventricular; BMI, body mass index;
BNP, B-type natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident; GFR, glomerular ﬁltration rate; IDCM, idiopathic
dilated cardiomyopathy; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
MR-proANP, midregional proatrial natriuretic peptide; NYHA, New York Heart Association.
Table 2 Univariate and multivariate continuous variable analysis of
baseline single-sample biomarkers for risk of death/cardiac
transplantation
Variable
HR (75th
relative to
25th centile)
Observed
25th and
75th quartiles p Value C-statistic
Univariate model
BNP (pg/ml) 2.10 73e458 <0.001 0.648
MR-proANP (pmol/l) 2.57 191e487 <0.001 0.735
Copeptin (pmol/l) 2.83 8e32 <0.001 0.670
Troponin T (ng/ml) 2.14 <0.01e0.03 <0.001 0.666
Multivariate model
BNP (pg/ml) 1.88 73e458 0.002 0.679
MR-proANP (pmol/l) 2.38 191e487 <0.001 0.758
Copeptin (pmol/l) 2.56 8e32 <0.001 0.740
Troponin T (ng/ml) 2.24 <0.01e0.03 <0.001 0.709
Biomarkers were added separately to the multivariate model which included NYHA class,
history of myocardial infarction, and presence of biventricular pacemaker. Models were
ﬁtted using natural log transformations of all continuous variables.
BNP, B-type natriuretic peptide; MR-proBNP, midregional proatrial natriuretic peptide.
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Biomarkers and heart diseasep¼0.001). For MR-proANP, tertile 2 (>227e412 pmol/l) was
signiﬁcantly different from tertile 1 (#227 pmol/l) (HR 4.79,
p¼0.004), as was tertile 3 (>412 pmol/l) (HR 10.66, p<0.0001).
Copeptin was similar to BNP in that tertile 2 (>10.2 to
25 pmol/l) was not different from tertile 1 (#10.2 pmol/l), while
tertile 3 (>25 pmol/l) was signiﬁcantly different from tertile 1
(HR 4.08, p<0.0001).
Analysis of changes in biomarkers over time
Table 4 shows the predicted risk associated with changes in MR-
proANP from one follow-up visit to the next relative to MR-
proANP concentrations remaining normal. An increase at any
time during follow-up carried a 4.35-fold increase in risk, which
was not, however, statistically signiﬁcant. This ﬁnding reﬂects
that the majority of patients had raised concentrations of MR-
proANP at study enrolment and thus few patients were in this
category of change (from normal to raised). However, modest
(<30%) increases or decreases (but not back to normal concen-
tration) from an already raised MR-proANP value were associ-
ated with a signiﬁcant change in risk (HR 5.79, p¼0.016).
Furthermore, large increases ($30%; a commonly cited level of
signiﬁcant change
6 8) from already raised values of MR-proANP
carried a very substantial increase in risk (HR 10.07, p¼0.002).
When the same analysis was carried out for copeptin (table 4),
only large increases ($30%) from already raised values were
associated with a further increase in risk (HR 11.48; p<0.001).
Raised values returning to normal during follow-up for either
peptide were not associated with mitigation of risk, but this
may reﬂect that few patients showed a lowering of values to
below the 95th centile during the study; therefore there were
too few patients in this category of change for meaningful
statistical analysis.
Time-dependent covariate biomarker analysis
Risk prediction by covariate analysis for MR-proANP and cTnT
when analysed for any time point during follow-up demonstrated
that an increase in MR-proANP without any increase in cTnT
predicted an increased risk of death/transplantation (HR 4.73,
95% CI 1.0 to 20.43, p¼0.037). When cTnTwas raised ($0.01 ng/
ml) without an increase in MR-proANP, the risk analysis was
confounded by too small a number of patients in this category.
However, the combined increases in cTnT and MR-proANP
augmented risk substantially (HR 10.29, 95% CI 2.48 to 42.67,
p¼0.0013). A similar analysis for copeptin showed that only the
combined increase with cTnT was associated with a signiﬁcant
increase in risk (HR 3.49, 95% CI 1.63 to 7.49, p¼0.0013).
Covariate time-dependent models for serial measurements of
MR-proANP and copeptin showed that neither biomarker, when
increased in isolation, was a signiﬁcant predictor. Combined
increases in both biomarkers, however, were associated with
increased risk (HR 9.01, 95% CI 1.24 to 65.26, p¼0.03). Of
particular interest is the observation in covariate analysis that
the individual and combined increases in MR-proANP and
copeptin when cTnTwas included in the analysis (but cTnTwas
not raised) were no longer predictive, and the associated HR
(5.93, 95% CI 0.78 to 45.11, p¼0.086) is lower than that noted
when cTnT was not included in the analysis (HR 9.01). The
combined increases in MR-proANP, copeptin and cTnT
predicted a substantial increase in risk (HR 11.07, 95% CI 1.52 to
Figure 1 KaplaneMeier curves for time-dependent event of death or
cardiac transplantation for (A) midregional proatrial natriuretic peptide
(MR-proANP) and (B) C-terminal provasopressin (copeptin) grouped by
category (increased (thin line; >95th centile of normal, adjusted for age
and gender, in (A) and >7.1 pmol/l for women and >9.4 pmol/l for men
in (B)) or not increased (thick line)) based on serial values over 2 years.
Table 3 Multivariate time-dependent analysis of risk for death/cardiac
transplantation (Cox proportional hazard model)
Variable HR (95% CI) p Value C-statistic
Raised BNP 1.39 (0.78 to 2.48) 0.258
Troponin T $0.01 ng/ml 2.18 (1.25 to 3.80) 0.006
NYHA class (IV vs III) 3.28 (1.63 to 6.61) <0.001
History of myocardial infarction 1.36 (0.80 to 2.32) 0.252
Biventricular pacemaker 3.42 (1.52 to 7.68) 0.003
Raised MR-proANP* 4.56 (1.08 to 19.32) 0.039 0.709
Raised copeptin* 1.86 (0.84 to 4.12) 0.126 0.705
*Each biomarker added separately to the multivariate model. B¼type natriuretic peptide;
BNP, NYHA, New York Heart Association; CI, conﬁdence interval; HR, hazard ratio; MR-
proANP, midregional proatrial natriuretic peptide.
Table 4 Effect of change in serial midregional proatrial natriuretic
peptide (MR-proANP) and C-terminal provasopressin (copeptin)
concentrations over the study period on outcome of death/cardiac
transplantation
Variable HR (95% CI) p Value C-Statistic
Normal to raised MR-proANP 4.35 (0.61 to 31.02) 0.143 0.641
Raised MR-proANP to <30%
change (increase or decrease
but none back to normal value)
5.79 (1.38 to 24.30) 0.016
Raised MR-proANP to $30%
further increase in MR-proANP
10.07 (2.34 to 43.38) 0.002
Normal to raised copeptin 4.11 (0.68 to 24.61) 0.122 0.684
Raised copeptin to <30%
change (increase or decrease
but none back to normal value)
4.20 (0.95 to 18.47) 0.058
Raised copeptin to $30% further
increase in copeptin
11.48 (2.74 to 48.08) <0.001
All values are relative to normal values remaining. CI, conﬁdence interval; HR, hazard ratio;
MR-proANP, mid-regional proatrial natriuretic peptide.
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Biomarkers and heart disease80.85, p¼0.02). This was, however, not much greater than the
combined increases in MR-proANP and cTnT when copeptin
was excluded (HR 10.29, p¼0.0013).
DISCUSSION
Effective risk stratiﬁcation is a key to success in the long-term
management of HF, particularly for outpatients. The results of
this study suggest that the conjoint use of MR-proANP with
cTnT in outpatients with chronic HF can aid in this strategy.
Indeed, in this dataset, MR-proANP provided more robust
responses than BNP in most analyses. Copeptin was less
robust. All the markers, as in other studies, demonstrated the
prognostic value of single-sample increases including BNP and
cTnT
6 92 9 e31; however, MR-proANP, and to a lesser extent
copeptin, seemed to add support for an incremental value of
serial measurements over time.
In categorical analysis, increases in MR-proANP and copeptin
at baseline (single samples) or during clinical follow-up (serial
samples) were univariately associated with an increased risk of
death or cardiac transplantation. New increases from normal
concentrations during follow-up did not statistically move
patients into a higher risk category, but this is most likely due to
the very high percentage (w70%) of patients entering the study
with already raised concentrations of these biomarkers by study
deﬁnition, and therefore relatively few patients were in this
category of change to allow analysis. However, once raised,
further increases signiﬁcantly shifted patients to a higher risk
category. These large increments (>30%) in MR-proANP and
copeptin deﬁned the outpatients who were at highest risk. The
large changes necessary to be clinically relevant once values are
raised are similar to previous data for BNP and NT-proBNP
where only large absolute or percentage changes were associated
with clinically meaningful alterations in risk.
32 For these
biomarkers, changes up to 80% were required to show signiﬁ-
cant differences. Values returning to normal for either of the
biomarkers did not mitigate risk, most likely because there were
small numbers of patients in this category of change.
Of additional importance is the observation that increases in
cTnT occurring at baseline or at any time during follow-up
dramatically modulate the risk-prediction capacity of MR-
proANPor copeptin. While MR-proANP showed an independent
contribution to risk stratiﬁcation in multivariate time-
dependent analysis, a substantial incremental effect was also
demonstrated when combined with cTnT. The interaction of
combined increases in MR-proANP, copeptin and cTnT proved
to be the most potent predictor of enhanced risk (HR 11.1,
p¼0.02), but not substantially different from the combined
increases in MR-proANP and cTnTwithout copeptin (HR 10.3,
p¼0.001). Increases in cTnT seem to have a potentiating effect
on the risk-predicting potential of increases in both MR-proANP
and copeptin. Surprisingly, copeptin was less robust in time-
dependent analyses with cTnT than MR-proANP, but this may
reﬂect differences in their pathophysiology. For copeptin to be
a more potent predictor of risk, more advanced HF reﬂective of
higher vasopressin release may be needed, as observed in
decompensated patients. In continuous variable multivariate
analysis using single-sample biomarker measurements, both
biomarkers were predictive in the presence or absence of raised
cTnT. This contrasts with the time-dependent categorical anal-
ysis (raised or not raised) where only MR-proANP remained
a statistically signiﬁcant independent predictor after adjustment
for cTnT and clinical risk factors. This suggests that deﬁning
appropriate cut-off point values is central to the practical clinical
use of these biomarkers in individual patients.
These ﬁndings suggest that the periodic monitoring of MR-
proANP, either separately or in combination with copeptin or
particularly with cTnT, after an initial increase may be an
effective means of deﬁning meaningful changes in risk and better
stratifying outpatients with HF. Our study population is similar
to many others, and thus results in both this study and other
analyses of other biomarkers should be helpful to physicians in
following patients with systolic HF. In addition, insights from
the impairment of these neurohormonal regulatory pathways
may aid in developing new strategies to preclude new increases
in these biomarkers or to intervene more effectively when they
occur and thus aid patient prognosis. This may be especially
promising for copeptin, serving as a surrogate for arginine
vasopressin, to be a reliable biomarker of therapeutic response to
vasopressin inhibition.
Limitations of the study
Of the study cohort, complete 2-year follow-up was not
accomplished in 18 patients for reasons other than the primary
end point. These patients elected not to continue participation
in the study, but six had completed at least 1 year of follow-up
and were censored at the time of their last visit. Eight patients
died after enrolment but before the ﬁrst 3-month follow-up visit
and therefore contributed only enrolment data, but were
considered part of the outcome analysis.
In conclusion, our data suggest that both clinically detectable
and subclinical events occur in patients with HF based on
discrete changes detected by serial biomarker surveillance, and
these occur in apparently clinically stable outpatients. In our
cohort, standard clinical assessment features such as change in
NYHA class or renal function were not altered substantially over
the course of the study to be a signal to the clinician of
advancing risk. Increases in MR-proANP and copeptin >95th
centile of normal population detected by serial monitoring
during follow-up in ambulatory patients appear to be common
and predictive of increased risk of short-term events including
death. The incremental predictive value of monitoring MR-
proANP over time alone, in combination with copeptin, and
particularly with cTnT, may provide an effective and simple
means of identifying ambulatory patients with HF who are at
increased risk and allow timely intervention. Overall, our data
also suggest that MR-proANP is equivalent, if not superior, to
BNP in risk prediction alone and in combination with cTnT. As
such, MR-proBNP should also be considered a candidate
biomarker in the developing area of natriuretic-peptide-guided
therapy in patients with HF.
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